Posted by Michael Wonder on 11 Jun 2020
'Imfinzi changed treatment paradigm for non-resectable non-small cell lung cancer'
10 June 2020 - The treatment has also become the first immunotherapy launched in Korea to receive health insurance benefits as consolidation therapy for non-small cell lung cancer from April 1.
Clinical results have shown that AstraZeneca's Imfinzi may be an effective option for non-resectable stage-3 non-small cell lung cancer, the company said Wednesday.
